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Abstract
Background: The close link between molecular subtypes and different histological types of breast cancer has recently been taken
into consideration.
Objectives: The present study aimed at evaluating the reproductive risk factors in relation to molecular subtypes and histological
features of breast cancer in a large group of Iranian patients.
Methods: This historical cohort study was conducted on 1988 women diagnosed as different subtypes of breast cancers recruited
in 2011 to 2016 from cancer research center in Shahid Beheshti University of Medical Sciences, Iran. Data on molecular markers
were obtained from hospital files obtaining originally from immunohistochemical staining technique. Based on the pathological
reports in hospital recorded files, the histological patterns of the cancer was also determined. The patients were followed for 5 years
to assess the 5-year survival and compared the survival across the different molecular subtypes.
Results: The highest mean age was found for the group with HER2-overexpression and the lowest for those with luminal A (P =
0.045). The most and the least tumor size was revealed in triple negative group and luminal A group, respectively (P = 0.035). The
mean number of lymph nodes involved in breast cancer was significantly higher in luminal B subtypes compared to luminal A
and triple negative subtypes (P = 0.004). The tumor stages III-IV were found in 31.6% of patients with luminal A subtype, 42.2% in
patients with luminal B, 34.3% in patients with HER2 overexpression, and 26.0% in those with triple negative subtype (P = 0.006). The
histological patterns of the tumor were powerfully different in terms of the molecular subtypes of tumor so that luminal A subtype
was found more in ILC pattern, luminal B subtype was found more in DCIS pattern, HER2-overexpression subtype was revealed more
in DCIS pattern, and triple negative subtype was found more in IDC pattern. Based on the long-term survival analysis, 5-year survival
was found to be 98.3% in luminal A group, 98.3% in luminal B group, 100% in HER2 overexpression, and 98.1% in triple negative with
no difference between different molecular subtypes. The lowest 5-year survival was found in the patients aged higher than 30 years
at first pregnancy and live birth with triple negative subtype (survival rate of 75.0%). The long-term survival was adversely associated
with the tumor stage but independent to tumor molecular subtypes.
Conclusions: Age at first live birth, tumor size, lymph node involvement, tumor stage, and histological pattern of breast cancer are
linked to its molecular subtype. The lower long-term survival of breast cancer can be predicted by advanced age (especially in triple
negative subtype) and by higher tumor stage independent to molecular subtype.
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1. Background
Nowadays, applying gene expression profiling tech-
nique successfully helps to classify breast cancer by deter-
mining specific molecular subtypes of cancer. The close
link between these subtypes and different clinical behav-
iors of breast cancers as well as its different response to
therapeutic chemotherapy regimens has also been iden-
tified (1, 2). It is, thus, suggested a significant association
between these molecular subtypes and known risk factors
for breast cancer through different etiological pathways (3,
4). For instance, in large nested case-control studies, mam-
mographic density was introduced as a strong risk factor
for breast cancer that was closely linked to some specific
molecular subtypes of breast cancer (5, 6). As another im-
portant factor, women age at menarche and at first birth
has been also pointed to be associated with cancer sub-
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types so that early menarche as well as late age at first
experience of delivery were linked to estrogen receptor
and/or progesterone receptor positive tumors compared
to hormone receptor negative tumors (7, 8). Body mass in-
dex (BMI), especially at menopausal ages, has been asso-
ciated with appearing some specific molecular subtypes
of breast cancers that women aged more than 50 years
with non-obese status predispose less to develop luminal
A-like breast cancers, while those women younger than 42
years with obese status were most likely to develop triple-
negative cancer (9). The duration of lactation has been
revealed as another factor linking specific molecular sub-
types of cancer. An inverse association has been shown be-
tween the presence of basal-like tumor and the duration of
lactation and, thus, prolonged lactation is now suggested
to be protective against basal-like breast cancer (7). Fortu-
nately, most traditional risk factors for breast cancer are
modifiable or manageable and, thus, by certainty to the
link between some risk factors and molecular breast can-
cer subtypes, controlling, and managing cancer-related
risk factors, the possibility to prevent different molecular
subtypes of cancers can be provided. In other words, due
to the wide variation of breast cancer risk factors by molec-
ular characteristics, better understanding of this link can
effectively help to prevent different molecular subtypes of
cancer by identifying and managing related clinical risk
factors. The present study aimed at evaluating the repro-
ductive risk factors in relation to molecular subtypes and
histological features of cancer in a large group of Iranian
women with breast cancer.
2. Methods
This historical cohort study was conducted on 1988
women diagnosed as different subtypes of breast cancers
recruited in 2011 to 2016 from cancer research center at
Shahid Beheshti University of Medical Sciences. Ethical ap-
provals were granted from the ethical board at Shaheed Be-
heshti University of Medical Sciences and all participants
gave written informed consent before participating into
the study. Exclusion criteria were missed information on
either of the immunohistochemistry (IHC) markers of tu-
mor or clinical characteristics that could not be corrected
by phone calling. Study baseline information on women
age, parity, weight and height, family history of breast
cancer, the duration of lactation, age at first birth, age
of menarche, and history of hormone replacement ther-
apy were all collected by viewing the hospital recorded
files. Data on molecular markers were obtained from hos-
pital files obtaining originally from immunohistochem-
ical (IHC) staining technique. Tumor cells that showed
any nuclear staining for estrogen receptor (ER) or proges-
terone receptor (PR) were considered ER (+) or PR (+), re-
spectively, whereas all ER (-) or PR (-) cases showed com-
plete absence of tumor cell staining in all tissue cores. Per-
cent ER and PR staining were dichotomized into positive
or negative status with a cutoff at ≥ 10% as positive (10).
HER2 status was dichotomized into positive or negative ac-
cording to the Pathology’s guidelines that HER2 was con-
sidered to be negative if protein expression showed 0 or
1+. Proliferation marker Ki67 was measured in hotspot
regions according to guidelines and reported as percent
staining. Information on tumor invasiveness and metas-
tasis was also collected by reviewing the recorded hospi-
tal documents. According to the rules of the categoriza-
tion of different breast cancer molecular subtypes, lumi-
nal A subtype was defined as ER+/PR+/HER2- and KI67 low,
luminal B as either ER+/PR-/HER2-, or ER+/PR+/HER2-, KI67
high, or ER+/HER2+/any PR, any KI67, HER2-overexpressing
as ER-/PR -/HER2 +, and basal-like as triple negative or ER-
/PR-/HER2- (10). Also, based on the pathological reports in
hospital recorded files, the cancers were categorized as in-
vasive lobular carcinoma, invasive ductal carcinoma, duc-
tal carcinoma in situ, and mixed pattern. The patients were
followed for 5 years and compared the survival across the
different molecular subtypes. Finally, data on reproductive
factors and other potential covariates as well as tumor spe-
cific classes were entered into the statistical datasheet for
final analysis.
For statistical analysis, the results were presented as
mean± standard deviation (SD) for quantitative variables
and were summarized by frequency (percentage) for cat-
egorical variables. Continuous variables were compared,
using ANOVA-post-hoc test. Categorical variables were, on
the other hand, compared, using Chi-square test. To as-
sess the long-term survival, the Log-rank test was applied
and the difference in survival between the groups was pre-
sented with the Kaplan-Meier curve. P values less than 0.05
were considered statistically significant. For the statistical
analysis, the statistical software SPSS version 23.0 for win-
dows (IBM, Armonk, New York) was used.
3. Results
3.1. Histological and Molecular Patterns Analysis
Initially, 1,016 patients were categorized in luminal A
subtype, 177 in luminal B subtype, 108 in HER2 overexpres-
sion subtype, and 220 in triple negative subtype. Regard-
ing the histological pattern of the tumor, 1,475 had IDC
pattern, 109 had DCIS pattern, 115 had ILC pattern, and 37
had mixed pattern, while histological pattern remained
unknown in 163 patients. Table 1 summarized the results
2 Int J Cancer Manag. 2018; 11(6):e66746.
Zeiyaie F et al.
related to comparing baseline characteristics across the
different molecular subgroups of cancer including lumi-
nal A, luminal B, HER2-overexpression, and triple negative.
Comparing mean age at the first pregnancy showed a sig-
nificant difference across 4 groups with the highest mean
age for the group with HER2-overexpression and the low-
est for those with luminal A (P = 0.045). Regarding tumor
size, a significant difference was found between the groups
with the different molecular subgroups with the most and
the least tumor size in triple negative group and luminal
A group, respectively (P = 0.035). In this regard, the fre-
quency of the size of more than 5mm was 8.4% in luminal A
group, 10.6% in luminal B group, 6.8% in HER2 overexpres-
sion group, and 14.6% in triple negative group. The mean
number of lymph nodes involved in breast cancer was sig-
nificantly higher in luminal B subtypes compared to lumi-
nal A and triple negative subtypes (P = 0.004). Similarly,
tumor stage was significantly different across 4 molecular
subtypes that the tumor stages III-IV was found in 31.6% of
patients with luminal A subtype, 42.2% in patients with lu-
minal B, 34.3% in patients with HER2 overexpression, and
26.0% in those with triple negative subtype (P = 0.006).
There was no difference across the different cancer molec-
ular subtypes with respect to the duration of lactation (P =
0.884) and number of gravity (P = 0.139). The histological
patterns of the tumor were powerfully different in terms
of the molecular subtypes of tumor so that luminal A sub-
type was found more in ILC pattern, luminal B subtype was
found more in DCIS pattern, HER2-overexpression subtype
was revealed more in DCIS pattern, and triple negative sub-
type was found more in IDC pattern. When considering
each histological pattern, the prominent molecular sub-
type in all histological patterns was luminal A as 56.6% in
IDC pattern, 43.1% in DCIS pattern, 70.4% in ILC group, and
62.2% in mixed group (Table 1).
3.2. Survival Analysis
In total, 1 474 out of 1 899 patients were successfully
followed-up with the overall follow-up rate of 82.1% and the
overall survival of 99.2%. Based on the long-term survival
analysis, 5-year survival was found to be 98.3% in luminal
A group, 98.3% in luminal B group, 100% in HER2 overex-
pression, and 98.1% in triple negative. According to the Log-
rank test, no difference was revealed between the molec-
ular subtypes in long-term survival. As shown in Table 2,
in the age at first live birth subgroup lower than 20 years,
no death was reported with the pointed follow-up time.
In age at first live birth subgroup 20 to 30 years, 2 events
was reported in triple negative subtype group, and in those
older than 30 years at first live birth, 1 death was reported
in triple negative subtype and another event in luminal A
subtype group. In this regard, the lowest 5-year survival
was found in the patients aged higher than 30 years at
first live birth with triple negative subtype (survival rate
of 75.0%). In different subgroups of lactation, long-term
death in the groups with lactation shorter than 12 months,
between 12 and 24 months and longer than 24 months was
1.31%, 0.45%, and 2.20%, respectively, with the overall sur-
vival rates of 98.7%, 99.5%, and 98.4%, respectively. No dif-
ference was revealed in long-term death across 4 molecu-
lar subtypes of cancer stratified according to the duration
of lactation (Table 2). Considering 3 groups of gravida as
0, 1 to 3, and > 3, the long-term death was found in 2.6%,
1.4%, and 1.2%, respectively. No difference was revealed in
long-term death across 3 groups. As indicated in Table 2,
in the different subgroups, according to the size of tumor
(< 2 mm, 2 - 5 mm, > 5 mm), no association was found be-
tween molecular subtype and long-term survival; however,
survival was adversely associated with the size of tumor.
Long-term death or survival of breast cancer was indepen-
dent to the number of involved lymph nodes. Similarly, no
relationship was revealed between molecular subtype and
long-term death or survival in different categories of the
lymph nodes involvement (Table 2). More importantly, the
long-term death was strongly associated with the tumor
stage as 0% in stage 0, 0% in stage I, 1.37% in stage II, 1.72%
in stage III, and 12.12% in stage IV. However, the association
between survival and tumor stage was not dependent to tu-
mor molecular subtypes.
4. Discussion
In the first step and of 1,899 patients with breast cancer,
the evidences of subtype heterogeneity were obtained for
some categories of risk factors including age at first preg-
nancy that was the highest in HER2-overexpression sub-
type and the lowest in luminal A subtype; tumor size that
was the most in triple negative subtype and the least in lu-
minal A subtype; the number of lymph nodes that was the
highest in luminal B subtype; and tumor stage that was the
highest and the lowest in luminal B and triple negative sub-
types, respectively. In other words, a close link was revealed
between molecular subtypes of the breast tumor and base-
line patients’ characteristics and tumor-related parame-
ters, especially size and stage of the tumor. More impor-
tantly, we found a close link between histological pattern
of breast cancer and its molecular subtype so that luminal
A subtype was found more in ILC pattern, luminal B sub-
type was found more in DCIS pattern, HER2-overexpression
subtype was revealed more in DCIS pattern, and triple neg-
ative subtype was found more in IDC pattern. In this study,
we had to ignore some other baseline factors such as body
mass index, history of HRT, and family history of cancer be-
cause of significant missing data related to these variables.
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Table 1. Comparing Baseline Variables Across the Different Molecular Subtypes
Item Luminal A Luminal B HER2 Overexpression Triple Negative P Value
Age at first pregnancy 22.86± 5.39 24.64± 5.63 24.68± 5.77 23.15± 5.66 0.039
Histology pattern, % < 0.001
IDC (1475) 56.6 10.1 6.1 12.9
DCIS (109) 43.1 11.0 9.2 11.9
ILC (115) 70.4 7.8 0.9 2.6
Mixed (37) 62.2 10.8 5.4 8.1
Tumor size, cm, % 0.143
< 2 (365) 34.4 21.1 32.5 29.5
2 - 5 (671) 57.1 68.3 57.1 62.0
> 5 (100) 8.4 10.6 10.4 8.4
Mean number of LN 2.49± 0.15 3.81± 0.45 2.76± 0.53 2.03± 0.31 0.004
Tumor stage, % 0.006
I (227) 21.3 10.2 20.6 19.6
II (677) 47.1 47.6 45.1 54.4
III (421) 28.8 39.8 34.3 24.5
IV (33) 2.8 2.4 0.0 1.5
Mean duration of lactation 2.343± 0.86 2.43± 0.85 2.50± 0.84 2.46± 0.87 0.884
Mean number of gravida 2.28± 1.68 2.03± 1.38 2.20± 1.33 2.44± 1.78 0.139
Interestingly, this study could not reveal any association
among molecular subtypes, the duration of breastfeeding,
and number of parity that were found to be inducible fac-
tors on heterogeneity of molecular tumor patterns.
The association between age at first pregnancy and in-
creased risk for breast cancer has been well defined. As de-
scribed by Lambe et al. (11), the risk of breast cancer in-
creased by about 13% for each 5-year increment in age at
first birth and for every 5 year-increase in age at last birth,
there was a small risk increase of marginal statistical sig-
nificance. The delay of first birth together with low parity
and short duration of breastfeeding are increasing social
trends in developed countries (12); however, the associa-
tion between age at first pregnancy and molecular subtype
has been less studied. As shown by Phipps et al. (13), age
at first birth was most strongly associated with risk of ER-
/PR-/HER2+ disease, but neither parity nor age at first birth
was associated with triple-negative breast cancer. Previous
studies of breast cancer overall have suggested that disease
risk is lower in women with a first birth at age < 20 than in
women with a first birth between ages 20 to 29 (14). Thus,
early age at first birth is associated with risk of ER+ but not
triple-negative breast cancer and, thus, it can be used for
discriminating HER2-overexpression subtype from other
subtypes. Regarding association between tumor size and
triple negative subtype, no previous evidence was reported
in similar results; however, it seems that larger tumor size
in this subtype leads to poorer prognosis of cancer (15, 16).
Similar to this survey, Ma et al. (17) could find that the tu-
mor size was significantly greater in triple negative sub-
type than other types. In total, larger size of tumor can
be predicted in triple negative subtype. We also showed
the link between the higher stage of tumor and luminal
B subtype. This association was similarly shown in other
population-based studies. As shown by Bediaga et al. (18),
comparison of the clinic-pathological features of the lumi-
nal samples clustered in luminal B and those clustered in
luminal A revealed higher stage in luminal B subtype. Also,
Serrano-Gomez et al. (19) showed the higher percentage of
stage III tumors in patients with luminal B subtypes.
The association between molecular types of breast can-
cer and its histological features has also been assessed in
different studies. In the present observation, luminal A
subtype was specified to ILC pattern, luminal B and HER2-
overexpression subtypes were specified to DCIS pattern,
and triple negative subtype was found more in IDC pattern.
Of course, this finding had not completely been in agree-
ment with other studies; thus; this specification may be
only observed in the population of the present study. In
a study conducted by Cherbal et al. (20) among Algerian
women with breast cancer, IDC feature was the most com-
mon histological type in all breast cancer subtypes. As in-
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Table 2. 5-Year Survival According to Baseline Variables in the Different Molecular Subtypes
Item Luminal A Luminal B HER2 Overexpression Triple Negative Overall
Total survival rate 98.3 98.3 100 98.1 98.4
Age at first pregnancy, y, %
< 20 100 100 100 100 100
20 - 30 100 100 100 94.4 99.2
> 30 96.7 100 100 75.0 96.1
Duration of lactation, mo, %
< 12 98.9 97.9 100 97.9 98.7
12 - 24 100 95.5 100 100 99.5
> 24 97.6 98.6 100 96.7 97.8
Number of gravida, %
0 97.1 94.1 100 100 97.3
1 to 3 98.8 97.8 100 97.1 98.6
> 3 98.5 100 100 98.4 98.7
Tumor size, cm, %
< 2 99.6 96.2 100 97.9 99.2
2 - 5 99.1 100 100 98.0 99.1
> 5 93.1 100 100 100 95.6
Lymph node, %
0 100 100 100 100 100
1 to 3 97.7 100 100 100 98.3
> 3 99.0 99.3 100 97.3 98.9
Tumor stage, %
I 100 100 100 100 100
II 98.4 100 100 98.1 98.6
III 98.8 95.4 100 97.9 98.3
IV 84.6 100 100 100 87.9
dicated by Doebar et al. (21), Her2+ invasive breast cancer
was associated with a higher prevalence of DCIS compared
to ER+/Her2- and triple-negative subtypes. However, in an-
other study performed by Perez et al. (22), there was no sig-
nificant difference in the immunophenotype frequencies
between pure ductal carcinoma in situ and ductal carci-
noma in situ associated with invasive carcinoma. It seems
that the association between histological and molecular
characteristics is strongly influenced by population char-
acteristics.
4.1. Conclusions
As we expected, the most important factors predicting
the survival of breast cancer were age and tumor stage,
while other variables such as lymph node involvement,
tumor size, the duration of lactation, and even molecu-
lar subtypes could not directly predict long-term survival.
Various studies assessed the predicting factors for long-
term survival in patients with breast cancer, especially in
some others, the presence of some molecular subtypes
such as ER-/HER2+ were associated with shorter long-term
survival (23). In a systematic review published in 2008, tu-
mor size, nodal status, and grade remained the most im-
portant prognostic factors for long-term survival between
1995 and 2006; however, their role decreased over time
till now (24). Similar to this study, in which the lowest 5-
year survival was found in the patients aged higher than
30 years at first pregnancy with live birth with triple neg-
ative subtype, breast cancer survival rates was shown to
be comparatively lower for women younger than 40 years
than for older women across all histological subtypes and
stages (25). Also, based on the results reported by Akbari et
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al. (26), histological grade and age at disease were also the
main aspects of correlation of death in patients with breast
cancer. Therefore, along with genetic and molecular fac-
tors as strong predictors for cancer survival, advanced age
and tumor stage can be considered other predictive mark-
ers for breast cancer.
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